Addressing the Data Gap in Rare Genetic Disease TRIAD

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has initiated a large-scale clinical study (NCT07683104) involving 750 participants to elucidate the natural history of TRIAD, a rare auto-inflammatory disease associated with Trisomy 8 Mosaicism. TRIAD is a debilitating rare disease characterized by uncontrolled inflammation due to genetic mutations; however, due to the extremely small patient population, there is a complete lack of systematic data on the long-term progression of the disease. This study is expected to address the data gap in the TRIAD market, where standardized treatments have not been established, and serve as a crucial foundation for establishing clinical endpoints for new drug development.

30-Year Longitudinal Tracking and Biomarker Acquisition

The clinical trial is designed as a long-term project, tracking patients for up to 30 years to record physical changes, going beyond simple short-term observation. Researchers will use advanced diagnostic techniques, including magnetic resonance imaging (MRI) and biopsies, to closely monitor subtle changes in the patients' major organs and bone marrow cells. This long-term data will be a key asset in identifying biomarkers at each stage of disease progression and is significant in that it will provide comparative data that can objectively demonstrate the efficacy of future new drug candidates.

Creating Opportunities for Targeted Treatment Through Differentiation from Behçet's Disease

TRIAD clinically presents with symptoms very similar to Behçet's Disease, such as recurrent fever, oral and genital ulcers, leading to a high rate of misdiagnosis and making it difficult to determine the appropriate timing for treatment. This study aims to establish a clear boundary between the two diseases by conducting detailed comparative analyses of the pathological mechanisms by which genetic mutations manifest as actual symptoms, including a healthy relative control group. This is expected to overcome the limitations of off-label use of existing immunomodulatory agents such as Otezla (apremilast, a PDE4 inhibitor) from Amgen and Humira (adalimumab, a TNF-alpha inhibitor) from AbbVie, and promote the development of dedicated TRIAD-specific new drugs.

Targeting the Niche Rare Disease Market Based on Unmet Medical Needs

The global market for Behçet's Disease treatments is estimated at approximately $300 million in 2026, and TRIAD is likely to be included as a high-risk sub-segment of this market. Although it is an ultra-rare disease, the total number of patients is small, but due to severe organ damage and high mortality rates that do not respond to existing treatments, it is a field with very strong unmet medical needs. With this clinical trial, the establishment of a biobank to secure patient-derived biological samples is expected to attract investment from venture capital (VC) and pharmaceutical companies seeking to secure a first-mover position in the development of next-generation immunomodulatory agents, following high-priced rare drugs such as Ilaris (canakinumab, an IL-1beta inhibitor) from Novartis.